Skip to main content

Advertisement

Table 1 Study population characteristics (n = 15)

From: A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

Age, mean (SD) 47.6 (10.7)
Race, n (%)
 White 14 (93)
 Black or African American 1 (7)
Sex, n (%)
 female 10 (67)
 male 5 (33)
Presence of ANA, n (%) 14 (93)
ANA Patterna, n (%)
 speckled 10 (67)
 homogeneous 4 (27)
 nucleolar 1 (7)
Scl-70 4 (27)
RNP 0
SSA/SSB 0
dsDNA 0
WBC (per μL), mean (SD) 7907 (2077)
ESRb, mean (SD), mm/h 15.4 (8.8)
Medication use, n (%)
 Antifibrotic agentc
  mycophenolate mofetil 12 (80)
  mycophenolic acid 2 (13)
  methotrexate 1 (7)
  cyclophosphamide 1 (7)
 prednisone
  (none) 9 (60)
  5 mg/d 3 (33)
  10 mg/d 1 (7)
 PPI 8 (53)
 CCB 4 (27)
 ACEi 5 (33)
 ARB 0
 statin 2 (13)
 ASA 5 (34)
 NSAID 1 (7)
Clinical symptoms, n (%)
 ILD 4 (27)
 SIBO 1 (7)
 GERD 9 (60)
 Hypothyroidism 2 (13)
 Raynaud’s 15 (100)
 DU 4 (27)
 GAVE 1 (7)
 Esophageal dysmotility 5 (33)
 Pericardial effusion 1 (7)
 SRC 1 (7)
 HTN 1 (7)
 Arthritis 2 (13)
 Sicca 1 (7)
 Calcinosis 1 (7)
 Intestinal Pseudobstruction 1 (7)
Disease duration months(SD)
 Raynaud’s 37 ± 40
 Skin sclerosis 19 ± 15
  1. ANA anti-nuclear antibody, ESR erythrocyte sedimentation rate, PPI proton pump inhibitor, CCB calcium channel blocker, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, NSAID non-steroidal anti-inflammatory drug, ILD interstitial lung disease, SIBO small intestinal bacterial overgrowth, GERD gastroesophageal reflux disease, DU digital ulcer, GAVE gastric antral vascular ectasia, SRC scleroderma renal crisis, HTN hypertension
  2. a1 patient had both a speckled and nucleolar pattern; 1 patient did not have the presence of an ANA detected; 1 patient’s ANA status was unknown
  3. b2 patients had unknown levels of ESR at study entry
  4. c1 patient received both cyclophosphamide and mycophenolate mofetil